| Literature DB >> 31161422 |
Alejandra de-la-Torre1, Claudia T Silva-Aldana2, Juliana Muñoz-Ortiz3,4, Laura B Piñeros-Hernández2, Oscar Otero4, Alejandra Domínguez3, León A Faciolince3,4, Mauricio Arcos-Holzinger3, Claudio Mastronardi5, Nora Constanza Contreras-Bravo2, Carlos Martín Restrepo2, Mauricio Arcos-Burgos6.
Abstract
Uveitis, defined as inflammation of the uveal tract of the eye, is a leading cause of blindness and visual impairment throughout the world. The etiology of uveitis is complex, and autoimmunity plays a major role in its pathogenesis. Intermediate uveitis (IU), a subtype of ocular inflammation, has been associated with systemic autoimmune disorders, specifically with multiple sclerosis (MS). This article reports a rare three-generation family with several members affected by IU (four siblings) and comorbid MS (two siblings fulfilling MS diagnostic criteria and a third sibling presenting some neurological symptoms). Based on the clinical findings, we captured and sequenced whole exomes of seven pedigree members (affected and unaffected). Using a recessive model of transmission with full penetrance, we applied genetic linkage analysis to define minimal critical regions (MCRs) in suggestive or nominal regions of linkage. In these MCRs, we defined functional (some pathogenic), novel, and rare mutations that segregated as homozygous in affected and heterozygous in unaffected family members. The genes harboring these mutations, including DGKI, TNFRSF10A, GNGT1, CPAMD8, and BAFF, which are expressed in both eye and brain tissues and/or are related to autoimmune diseases, provide new avenues to evaluate the inherited causes of these devastating autoimmune conditions.Entities:
Keywords: Genetics; Multiple sclerosis; Mutations; Pedigree; Uveitis; Whole exome sequencing
Mesh:
Year: 2019 PMID: 31161422 PMCID: PMC6834745 DOI: 10.1007/s12035-019-1630-2
Source DB: PubMed Journal: Mol Neurobiol ISSN: 0893-7648 Impact factor: 5.590
Fig. 1Genealogy segregating intermediate uveitis (IU) and multiple sclerosis (MS). Intermediate uveitis (black signals condition of interest). Comorbid multiple sclerosis (asterisk)
Fig. 2Retinal fluorescein angiography and fundus photography EMU005. a Papillitis (circle), cystoid macular edema (white arrow), perivasculitis (black arrows), and retinitis (asterisk). b Exudative retinal detachment (black arrows). c Intraretinal hemorrhage (asterisk) and retinal detachment (black arrow)
Eye signs and symptoms in siblings affected by IU and/or MS
| Patient | Age of onset of ocular symptoms (y/o) | Ocular symptoms | BCVA at onset | Ophthalmologic findings | Diagnosis | Last BCVA | Treatment |
|---|---|---|---|---|---|---|---|
| M-XY EMU003 | 12 | Asymptomatic (evaluation after family history) | OD 20/20 OS 20/20 | OD: vascular sheathing, vitreoussnowballs. OS: no inflammatory involvement. | Intermediate uveitis | OD 20/20 OS 20/20 | Observation |
| M-XY M004 | 24 | Asymptomatic (evaluation after family history) | OD 20/40 OS 20/50 | OD posterior subcapsular cataract > OS OS: vitritis, snowballs and snowbanks. | Intermediate uveitis | OD 20/30 OS 20/50 | Topic and injected periocular steroids. Systemic corticosteroids, prednisolone, and systemic immunosuppressant, methotrexate |
| F-XX EMU005 | 11 | FloatersDecreased vision OD | OD 20/40 OS 20/15 | OD: retinal detachment OS: vitritis, peripheral retinal detachment, dense snowballs. | Intermediate uveitis | OD NLP OS 20/20 | Topic and injected periocular steroids. Systemic corticosteroids, prednisolone, and systemic immunosuppressant, methotrexate (higher doses). |
| F-XX EMU002 | 10 | Decreased vision OD | OD 20/800 OS 20/20 | OD: retinal detachment OS: vitritis, snowballs, posterior subcapsular cataract. | Intermediate uveitis | OD NLP OS 20/30 | Topic and injected periocular steroids. Systemic corticosteroids, prednisolone, and systemic immunosuppressant, methotrexate (higher doses). |
BCVA best corrected visual acuity, OD right eye, OS left eye, NLP no light perception
Neurological signs and symptoms in siblings affected by IU and/or MS
| Patient | Age of onset (y/o) of neurological symptoms | Neurological symptoms | Neurological findings | MRI findings | Neurological Dx | Treatment |
|---|---|---|---|---|---|---|
| M-XY EMU003 | – | – | – | – | None. Patient died in an accident before knowing if he had MS findings. | Observation. |
| M-XY EMU004 | 17 | Fatigue in lower limbs. Anxiety. | – | Refuses to diagnose confirmation. | Neurological symptoms suggesting MS comorbidity Fatigue syndrome in lower limbs. Generalized anxiety syndrome (psychiatric diagnosis). | Systemic corticosteroids, prednisolone, and systemic immunosuppressant, methotrexate. |
| F-XX EMU005 | 22 | Decrease strength and sensitivity of the body right half. Decrease in sensation of the right upper limb. | Right Babinski (+). Right pyramidal motor syndrome. Right hypoesthesia. Hemiparetic gait. Hypoesthesia of the right upper limb. Left hemiparesis. Strength 3/5. Left hypoesthesia. | 22-year-old brain MRI: Small punctate lesions in the white matter of semi-oval centers of both hemispheres. Spine MRI (cervical): punctate focal lesion of the cord at C3 level without signs of inflammatory activity. 27-year-old brain MRI: multiple periventricular lesions, two of them have enhancement with contrast medium indicating activity. Spine MRI: presence of cervical and thoracic demyelinating plaques. 33-year-old brain MRI: 10 new lesions and volume loss of the cerebral parenchyma. Spine MRI (cervical): The lesions described are more confluent and are associated with a discrete decrease in the volume of the cord. | Multiple sclerosis 2017 McDonald criteria: ≥ 2 attacks and objective clinical evidence of ≥ 2 lesions. CSF-specific oligoclonal bands | Systemic corticosteroids, prednisolone, and systemic immunosuppressant, methotrexate. |
| F-XX EMU002 | 19 | Alteration of balance. Paresthesia in hands and head. Urine retention. | Romberg +. Dysdiadochokinesia. Neurogenic bladder. | Previous images not available. 32-year-old brain MRI: multiple supra and infratentorial hyperintense lesions in T2 and FLAIR sequence. Presence of black holes and active lesions. Spine MRI (cervical): hyperintense cervical and dorsal lesions. Atrophy of the medullary cord. No active lesions. | Multiple sclerosis 2017 McDonald criteria: ≥ 2 attacks and objective clinical evidence of ≥ 2 lesions. CSF-specific oligoclonal bands | Systemic corticosteroids, prednisolone, and systemic immunosuppressants, methotrexate. |
MRI magnetic resonance imaging
Fig. 3Brain IRM FLAIR sequence year 2007 (a), 2011 (b), and 2012 (c). Bilateral progressive periventricular hyperintensities around the posterior horns of the lateral ventricles (white arrows)
Fig. 4a Contrasted brain MRI T1 sequences (2017). High uptake images along the supramarginal gyrus in the caudal aspect of the left parietal lobe (white arrows). b No contrasted brain MRI T1 sequences (2017). Hypointense sphere-like image in the caudal aspect of the left parietal lobe (white arrows)
Fig. 5a Cervical spine MRI T2 sequences (May 2011). Diffuse hyperintensities of poorly defined borders, in C2–C3 down to the inferior plate of C5 vertebral body (asterisk). b Cervical spine MRI T2 sequences (2012). Hypertense image in in medulla-spinal border down to the inferior plate of C2 (asterisk)
Parametric and non-parametric estimated LOD scores in regions with suggestive and nominal genetic linkage with the list of genes contained in minimal critical regions defined by the 1-LOD score criterion
| Chr | Position | 1-LOD score lower | 1-LOD score upper | LODMAX | NPL SPAIR | NPL SALL | Genes |
|---|---|---|---|---|---|---|---|
| 1 | 145112414 | 0.905867 | 1.470478 | 1.806331 | 3.464102 | 3.684484 | |
| 2 | 130951584 | 0.946075 | 1.377104 | 1.805566 | 3.464102 | 3.684484 | |
| 6 | 57467303 | 1.1247 | 1.4644 | 1.7774 | |||
| 7 | 128315882 | 1.230381 | 0.234805 | 1.805566 | 3.464102 | 3.684483 | |
| 9 | 68433567 | 0.802898 | 1.312274 | 1.557544 | 2.697369 | 2.819446 |
|
| 10 | 46999151S | 1.355892 | 1.507883 | 1.805282 | 3.462968 | 3.683198 | |
| 11 | 104768909 | 1.2454 | 0.6977 | 1.8056 | |||
| 13 | 19239331 | 1.708426 | 1.374161 | 1.710696 | 3.092112 | 3.264238 |
|
| 14 | 90730265 | 0.535392 | 1.433905 | 1.805566 | 3.464102 | 3.684484 | |
| 15 | 101827759 | 1.276506 | 1.804787 | 1.805562 | 3.464085 | 3.684465 |
List of novel and rare variants with functional effects in genes from the minimal critical regions cosegregating as homozygous in affected individuals (IU and/or MS) and heterozygous in unaffected individuals (in agreement with the recessive model of transmission). These variants are predicted to trigger functional consequences
| Chromosome | Position | Gene | EMU-001 | EMU-002 | EMU-003 | EMU-004 | EMU-005 | EMU-006 | EMU-007 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Novel | *7 | 137092781 | DGKI | C_T | C_C | C_C | C_C | C_C | C_T | C_T |
| Novels | 7 | 93540348 | GNGT1 | G_T | G_G | G_G | G_G | G_G | G_T | G_G |
| *7 | 137092781 | DGKI | C_T | C_C | C_C | C_C | C_C | C_T | C_T | |
| Pathogenic | 8 | 23059324 |
| C_G | G_G | G_G | G_G | G_G | C_G | G_G |
| 8 | 23,060,256 |
| C_T | C_C | C_C | C_C | C_C | C_T | C_C | |
| 19 | 17108135 |
| C_T | T_T | T_T | T_T | T_T | C_T | C_T | |
| Indels | 7 | 103207412 | RELN | -_AAGGAAA | AAGGAAA_AAGGAAA | AAGGAAA_AAGGAAA | AAGGAAA_AAGGAAA | AAGGAAA_AAGGAAA | ?_? | -_AAGGAAA |
| 7 | 103234986 | -_T | T_T | T_T | T_T | T_T | ?_? | -_T | ||
| 7 | 103314360 | -_CTC | CTC_CTC | CTC_CTC | CTC_CTC | CTC_CTC | ?_? | -_CTC | ||
| 13 | 108959081 | TNFSF13B | -_T | T_T | T_T | T_T | T_T | ?_? | T_T |